<?xml version="1.0" encoding="UTF-8"?>
<p>A total of three studies were identified, of which two were deemed suitable for inclusion (
 <xref rid="Stable3" ref-type="table">Supplementary Table 3</xref>). The first study was a research letter that suggested that TNFa has been implicated in the severe immune-based pulmonary injury caused by SARS coronavirus, suggesting that TNFa inhibitors could be a potential treatment for the acute respiratory disease syndrome caused by coronavirus [
 <xref rid="ref21" ref-type="bibr">21</xref>]
</p>
